Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on X:
“Breaking: HER2CLIMB-05
Pfizer reports positive Phase 3 results — adding TUKYSA (tucatinib) to trastuzumab plus pertuzumab maintenance significantly improves PFS in first-line HER2 positive metastatic breast cancer.
- Trial: HER2CLIMB-05
- Setting: 1L maintenance after chemotherapy plus HP
- Result: PFS versus placebo
- Drug: TUKYSA plus HP
First frontline advance since CLEOPATRA 2012”
Erika Hamilton shared a post by Amol Akhade, adding:
“Now for the fun – we are likely to have multiple options in 1L HER-2 positive BCSM.
- 1L THP to TH plus tucatinib (HER2CLIMB-05)
- 1L THP to TH plus AI plus palbo (PATINA)
- 1L TDX-d to plus/minus maintenance? (DB-09)
Desire for maintenance strategy I think remains high (efficacy, QOL, tolerability)!”
Pfizer Announced Positive Topline Results from the Phase 3 HER2CLIMB-05 trial
